HDL-C Response Variability to Niacin ER in US Adults
Table 1
Baseline characteristics and lipid levels1.
Demographics and lipids
500 mg niacin ER dose ()
1000 mg niacin ER dose ()
(%)
(%)
Age (years)
18 to 40
79 (11.6)
12 (7.8)
41 to 65
516 (75.9)
131 (85.1)
≥66
85 (12.5)
11 (7.1)
Gender
Male
480 (70.6)
120 (77.9)
Female
200 (29.4)
34 (22.1)
HDL-C mg/dL (both genders)
<40
419 (61.6)
87 (56.5)
40 to 59
213 (31.3)
59 (38.3)
≥60
44 (6.5)
8 (5.2)
Baseline LDL-C mg/dL
<130
266 (39.1)
87 (56.5)
≥130
178 (26.2)
34 (22.1)
Unknown
236 (34.7)
33 (21.4)
Baseline TG mg/dL
<150
192 (28.2)
60 (39.0)
≥150
483 (71.0)
93 (60.4)
Unknown
5 (0.7)
1 (0.7)
Baseline TC mg/dL
<200
301 (44.3)
96 (62.3)
≥200
375 (55.2)
57 (37.0)
Unknown
4 (0.6)
1 (0.7)
Comorbidities
Diabetes
188 (27.7)
41 (26.6)
Stroke (within 6 months)
26 (3.8)
10 (6.5)
Hypertension (within 6 months)
46 (6.8)
7 (4.6)
Ischemic heart disease (within 6 months)
130 (19.1)
32 (20.8)
Medication use
Prestatin users
258 (37.9)
64 (41.6)
Prefibric acid users
82 (12.1)
12 (7.8)
Persistence
Average persistence (days)
193.6
192.1
≥365 days persistence
79 (11.6)
17 (11.0)
<365 days persistence
601 (88.4)
137 (89.0)
Lipid levels were measured within six months prior to any niacin ER use. Definition of lipids: HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; TG: triglycerides; TC: total cholesterol.
